Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment.
- Author:
Haili MA
1
;
Siye CHEN
1
;
Yan HE
1
;
Jingwei HUANG
1
;
Yanhong XU
1
;
Chao WANG
2
;
Cheng LEI
1
;
Ting LU
1
;
Shengdong XIAO
1
;
Jinming MAO
1
;
Yiyun XU
1
;
Hao GUO
1
;
Bohua LI
1
;
Minghui ZHANG
2
;
Xiaowen HE
3
Author Information
- Publication Type:Letter
- MeSH: Antineoplastic Agents; chemistry; pharmacology; Carcinoma, Hepatocellular; drug therapy; immunology; pathology; Cytokines; immunology; Drug Screening Assays, Antitumor; Glypicans; antagonists & inhibitors; immunology; Humans; Ligands; Liver Neoplasms; drug therapy; immunology; pathology; T-Lymphocytes; drug effects; immunology
- From: Protein & Cell 2018;9(7):664-669
- CountryChina
- Language:English
